504
report
Financing Global Early Warning Systems Country Case Study: Indonesia
Indonesia grappled with one of Southeast Asia’s highest COVID-19 caseloads, reporting nearly 7 mill
ion cases and 161,918 deaths as of December 2023. The pandemic’s ripple effects extended beyond the immediate health crisis.
+ Read More
report
Financing Global Early Warning Systems: Brazil
During COVID-19, Brazil recorded the second-highest global mortality rate, with ripple effects exte
nding to the economy. Unemployment surged to over 13 percent, and economic growth contracted by more than 3 percent in the first year of the pandemic.
+ Read More
report
Financing Global Early Warning Systems Country Case Study: Kenya
Kenya experienced a significant economic slowdown during the COVID-19 pandemic. Kenya’s extensive a
viation connections throughout Africa, Europe, and Asia make Kenya one of the fastest-growing economies in Africa.
+ Read More
report
Employer Investments in Digital, Whole-Person Health for Substance Use Disorders
Employers seek to support their employees while normalizing a whole-person approach to substance us
e disorders (SUD). The response to addiction and the opioid crisis requires a whole-of-society approach, including employers of all sizes.
+ Read More
report
Toward a National Action Plan for Achieving Diversity in Clinical Trials
Participation in clinical research among racial and ethnic minorities remains low, even though such
groups now represent nearly 40 percent of the US population.
+ Read More
panel
Networking and Refreshment Break
panel
Networking and Refreshment Break
panel
Lunch Simulcast
panel
Lunch Simulcast
panel
Flipping the Script: Designing the System to Deliver for Patients
An outgrowth of consumerism in all aspects of health and health care is the expectation that pat
ients must be a critical partner in the design of solutions intended to improve their health.
+ Read More
panel
Moderators - All Statuses - No Panel Placement
panel
21st Century Cures 2.0: What's Next (Invite only)
21st Century Cures was a sweeping piece of legislation aimed at revamping the biomedical R&D
system. Three years later, what has the impact been? What more remains to be done?
+ Read More